AdaptVac has announced the publication of strong virus neutralization animal proof-of-concept data for its capsid virus like particle (cVLP) based SARS-CoV-2 subunit vaccine in Nature Communications.
The vaccine elicited antibodies in mice which effectively prevented live SARS-CoV-2 virus from infecting and killing human cells in an in vitro assay.
The project remains on track for delivery of initial PhI/IIa results in Q1 2021, states the company further.
PREVENT-nCoV consortium
The result was obtained through the combined efforts of PREVENT-nCoV consortium partners and Aarhus University. ExpreS2 ion Biotechnology produced the SARS-CoV-2 Spike protein variant, while AdaptVac displayed the antigen on its capsid Virus-Like Particle. This was followed by vaccination studies in mice at University of Copenhagen, and finally analysis of the raised antibodies’ capability to neutralize live SARS-CoV-2 virus in the lab through in vitro studies by the groups of Associate Prof. Marjolein Kikkert, Leiden University Medical Centre and Prof. Søren Riis Paludan, Aarhus University.
The article is titled “Capsid-like particles decorated with the SARSCoV-2 receptor-binding domain elicit strong virus neutralization activity”
“Publication of our cVLP vaccine animal proof-of-concept results in the high-impact journal Nature Communications once again demonstrates the quality of the research performed by the PREVENT-nCoV consortium and the exceptional promise of this vaccine.”, says Wian de Jongh, AdaptVac’s CEO.
Photo: Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland.
Credit: NIAID-RML
